Eaton Vance Management Halozyme Therapeutics, Inc. Transaction History
Eaton Vance Management
- $67.5 Billion
- Q3 2022
A detailed history of Eaton Vance Management transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Eaton Vance Management holds 139,396 shares of HALO stock, worth $7.25 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
139,396
Previous 139,453
0.04%
Holding current value
$7.25 Million
Previous $6.14 Million
10.19%
% of portfolio
0.01%
Previous 0.01%
Shares
11 transactions
Others Institutions Holding HALO
# of Institutions
441Shares Held
122MCall Options Held
216KPut Options Held
140K-
Black Rock Inc. New York, NY18.2MShares$949 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA13MShares$679 Million0.01% of portfolio
-
State Street Corp Boston, MA6.49MShares$337 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.12MShares$214 Million3.73% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.79MShares$197 Million0.24% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.25B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...